{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:13:24Z","timestamp":1767651204161},"reference-count":72,"publisher":"American Diabetes Association","issue":"Supplement_2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"DOI":"10.2337\/dcs13-2012","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T15:09:50Z","timestamp":1374678590000},"page":"S180-S189","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":13,"title":["How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment"],"prefix":"10.2337","volume":"36","author":[{"given":"Baptist","family":"Gallwitz","sequence":"first","affiliation":[{"name":"Department of Medicine IV, Eberhard-Karls University, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard G.","family":"Bretzel","sequence":"additional","affiliation":[{"name":"Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2013,7,17]]},"reference":[{"key":"2022031219433601800_B1","unstructured":"International Diabetes Federation. Diabetes atlas [article online], 2011. Available from http:\/\/www.idf.org\/diabetesatlas\/5e\/the-global-burden. Accessed 14 December 2012"},{"key":"2022031219433601800_B2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031219433601800_B3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031219433601800_B4"},{"key":"2022031219433601800_B5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B6","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"2022031219433601800_B7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031219433601800_B8"},{"key":"2022031219433601800_B9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2165\/11592810-000000000-00000","article-title":"Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents","volume":"71","author":"Gallwitz","year":"2011","journal-title":"Drugs"},{"key":"2022031219433601800_B10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/11319130-000000000-00000","article-title":"Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus","volume":"33","author":"Gallwitz","year":"2010","journal-title":"Drug Saf"},{"key":"2022031219433601800_B11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1463-1326.2012.01574.x","article-title":"Liraglutide in oral antidiabetic drug combination therapy","volume":"14","author":"Garber","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031219433601800_B12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly glucagon-like peptide-1 receptor agonists\u2014available efficacy and safety data and perspectives for the future","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031219433601800_B13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2022031219433601800_B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"2022031219433601800_B15","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"key":"2022031219433601800_B16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"2022031219433601800_B17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","article-title":"A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study","volume":"50","author":"Nauck","year":"2007","journal-title":"Diabetologia"},{"key":"2022031219433601800_B18","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinthera.2007.11.006","article-title":"Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial","volume":"29","author":"Barnett","year":"2007","journal-title":"Clin Ther"},{"key":"2022031219433601800_B19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1185\/03007990802597951","article-title":"Efficacy and safety of biphasic insulin aspart 70\/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea","volume":"25","author":"Bergenstal","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2022031219433601800_B20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc10-1900","article-title":"Exenatide twice daily versus premixed insulin aspart 70\/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia","volume":"34","author":"Gallwitz","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B21","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of \u03b2-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/dc11-1233","article-title":"Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks","volume":"35","author":"Diamant","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B23","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"2022031219433601800_B24","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1463-1326.2011.01436.x","article-title":"Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials","volume":"13","author":"Wang","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031219433601800_B25","unstructured":"Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation (LEADER) [article online], 2012. Available from http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01179048. Accessed 17 June 2012"},{"key":"2022031219433601800_B26","unstructured":"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus [article online]. Available from http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01144338. Accessed 17 June 2012"},{"key":"2022031219433601800_B27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B28","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(09)60619-X","article-title":"Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study","volume":"373","author":"Tab\u00e1k","year":"2009","journal-title":"Lancet"},{"key":"2022031219433601800_B29","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"U.K. prospective diabetes study 16. Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease","volume":"44","author":"U.K. Prospective Diabetes Study Group","year":"1995","journal-title":"Diabetes"},{"key":"2022031219433601800_B30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M","article-title":"Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study","volume":"15","author":"Levy","year":"1998","journal-title":"Diabet Med"},{"key":"2022031219433601800_B31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"2022031219433601800_B32","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1007\/s00125-012-2466-8","article-title":"Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans","volume":"55","author":"Meier","year":"2012","journal-title":"Diabetologia"},{"key":"2022031219433601800_B33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1464-5491.2009.02847.x","article-title":"Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies","volume":"26","author":"Del Prato","year":"2009","journal-title":"Diabet Med"},{"key":"2022031219433601800_B34","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.2337\/dc11-s224","article-title":"Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes","volume":"34","author":"Bolli","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B35","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on \u03b2-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet"},{"key":"2022031219433601800_B36","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(08)60736-9","article-title":"Intensive insulin therapy in newly diagnosed type 2 diabetes","volume":"371","author":"Retnakaran","year":"2008","journal-title":"Lancet"},{"key":"2022031219433601800_B37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MCO.0b013e3281e38774","article-title":"Anti-inflammatory effects of insulin","volume":"10","author":"Dandona","year":"2007","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2022031219433601800_B38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/01.ATV.0000113817.48983.c5","article-title":"3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes","volume":"24","author":"Vehkavaara","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031219433601800_B39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0029-1212082","article-title":"Insulin signal transduction: possible mechanisms for insulin resistance","volume":"107","author":"Kellerer","year":"1999","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2022031219433601800_B40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1210\/jcem-42-2-222","article-title":"Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests","volume":"42","author":"Brunzell","year":"1976","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031219433601800_B41","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.2337\/dc11-0471","article-title":"Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes","volume":"34","author":"Pennartz","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B42","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1463-1326.2010.01209.x","article-title":"Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial \u03b2-cell protection in individuals with type 2 diabetes","volume":"12","author":"Forst","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2022031219433601800_B43","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.clinthera.2007.07.005","article-title":"Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy","volume":"29","author":"Vinik","year":"2009","journal-title":"Clin Ther"},{"key":"2022031219433601800_B44","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"Holman","year":"2007","journal-title":"N Engl J Med"},{"key":"2022031219433601800_B45","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","article-title":"Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial","volume":"371","author":"Bretzel","year":"2008","journal-title":"Lancet"},{"key":"2022031219433601800_B46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00508-009-1209-4","article-title":"The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus","volume":"121","author":"Ludvik","year":"2009","journal-title":"Wien Klin Wochenschr"},{"key":"2022031219433601800_B47","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1210\/jc.2007-2871","article-title":"Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes","volume":"93","author":"Linn","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031219433601800_B48","first-page":"1","article-title":"Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine","volume":"12","author":"Bretzel","year":"2009","journal-title":"J Media Econ"},{"key":"2022031219433601800_B49","first-page":"952","article-title":"Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study","volume":"29","author":"Peyrot","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B50","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.2337\/dc09-S319","article-title":"Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond","volume":"32","author":"Bretzel","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B51","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"2022031219433601800_B52","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1463-1326.2011.01412.x","article-title":"An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia","volume":"13","author":"Fonseca","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031219433601800_B53","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B54","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-5491.2006.01881.x","article-title":"A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and\/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study","volume":"23","author":"Gerstein","year":"2006","journal-title":"Diabet Med"},{"key":"2022031219433601800_B55","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"Yki-J\u00e4rvinen","year":"2006","journal-title":"Diabetologia"},{"key":"2022031219433601800_B56","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc06-1357","article-title":"Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups","volume":"30","author":"Yki-J\u00e4rvinen","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.29.01.06.dc05-1058","article-title":"Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial","volume":"29","author":"Kennedy","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1463-1326.2006.00593.x","article-title":"Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients","volume":"9","author":"Schreiber","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"2022031219433601800_B59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/dia.2007.0265","article-title":"The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice","volume":"10","author":"Schreiber","year":"2008","journal-title":"Diabetes Technol Ther"},{"key":"2022031219433601800_B60","first-page":"91","article-title":"EARLY study: early basal insulin therapy under real-life conditions in type 2 diabetics","volume":"21","author":"Hanefeld","year":"2012","journal-title":"Diabetes Stoffw Herz"},{"key":"2022031219433601800_B61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/dmrr.1288","article-title":"Strategies for insulin initiation: insights from the French LIGHT observational study","volume":"28","author":"Verg\u00e8s","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031219433601800_B62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/dia.2011.0220","article-title":"Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis","volume":"14","author":"Odawara","year":"2012","journal-title":"Diabetes Technol Ther"},{"key":"2022031219433601800_B63"},{"key":"2022031219433601800_B64","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2022031219433601800_B65","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary","volume":"28","author":"Ryd\u00e9n","year":"2007","journal-title":"Eur Heart J"},{"key":"2022031219433601800_B66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1463-1326.2011.01512.x","article-title":"Proportion of patients at HbA1c target &lt;7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients","volume":"14","author":"Esposito","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031219433601800_B67","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/dmrr.733","article-title":"When basal insulin therapy in type 2 diabetes mellitus is not enough\u2014what next?","volume":"23","author":"Raccah","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031219433601800_B68","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1089\/dia.2012.0022","article-title":"Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease","volume":"14","author":"Lebovitz","year":"2012","journal-title":"Diabetes Technol Ther"},{"key":"2022031219433601800_B69","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.clinthera.2009.07.021","article-title":"Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting","volume":"31","author":"Yoon","year":"2009","journal-title":"Clin Ther"},{"key":"2022031219433601800_B70","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/dc09-2191","article-title":"Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study","volume":"33","author":"Arnolds","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031219433601800_B71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"2022031219433601800_B72","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00125-009-1352-5","article-title":"Megatrials in type 2 diabetes. From excitement to frustration?","volume":"52","author":"Del Prato","year":"2009","journal-title":"Diabetologia"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/Supplement_2\/S180\/483098\/s180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/Supplement_2\/S180\/483098\/s180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T21:26:10Z","timestamp":1647120370000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/Supplement_2\/S180\/30018\/How-Do-We-Continue-Treatment-in-Patients-With-Type"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,17]]},"references-count":72,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2013,7,17]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dcs13-2012","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,17]]}}}